APLS
Apellis Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Apellis Pharmaceuticals, Inc. (APLS) closed at $41.03 as of 2026-05-15, trading 3.9% below its 200-week moving average of $42.68. This places APLS in the below line zone. The stock moved further from the line this week, up from -3.9% last week. With a 14-week RSI of 78, APLS is in overbought territory.
A big spike in selling this week — 3.0x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 396 weeks of data, APLS has crossed below its 200-week moving average 5 times. On average, these episodes lasted 30 weeks. Historically, investors who bought APLS at the start of these episodes saw an average one-year return of +71.7%.
With a market cap of $5.3 billion, APLS is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at 46.0%, indicating strong profitability. The stock trades at 12.7x book value.
Share count has increased 14.3% over three years, indicating dilution.
Over the past 7.7 years, a hypothetical investment of $100 in APLS would have grown to $274, compared to $314 for the S&P 500. APLS has returned 14.0% annualized vs 16.1% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: APLS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After APLS Crosses Below the Line?
Across 5 historical episodes, buying APLS when it crossed below its 200-week moving average produced an average return of +45.4% after 12 months (median +64.0%), compared to +9.2% for the S&P 500 over the same periods. 80% of those episodes were profitable after one year. After 24 months, the average return was +65.8% vs +33.2% for the index.
Each line shows $100 invested at the moment APLS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices APLS would reach each dislocation threshold.
Dislocation Price Levels
Prices where APLS's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-07-30.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $19.95 | Unusually cheap — potential buy zone |
| Value | +1σ | $24.67 | Cheap vs. own history |
| Fair Value | +0σ | $32.30 | Historical mean behavior |
| Expensive | -1σ | $46.77 | Expensive vs. own history |
| Deep Expensive | -2σ | $84.75 | Unusually expensive — potential trim zone |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from APLS's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
APLS has crossed below its 200-week MA 5 times with an average 1-year return of +71.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 2018 | Feb 2019 | 19 | 31.4% | +107.1% | +205.4% |
| May 2019 | May 2019 | 1 | 1.2% | +72.2% | +127.9% |
| Oct 2021 | Nov 2021 | 1 | 0.5% | +97.1% | +33.5% |
| Jul 2023 | Nov 2023 | 19 | 48.3% | +10.4% | +19.3% |
| Apr 2024 | Ongoing | 109+ | 64.4% | Ongoing | -13.7% |
| Average | 30 | — | +71.7% | — |
Frequently Asked Questions
Is APLS below its 200-week moving average?
Yes. As of 2026-05-15, Apellis Pharmaceuticals, Inc. (APLS) is trading 3.9% below its 200-week moving average of $42.68. The current price is $41.03.
What is APLS's 200-week moving average price?
Apellis Pharmaceuticals, Inc.'s 200-week moving average is $42.68 as of 2026-05-15. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when APLS drops below its 200-week moving average?
APLS has crossed below its 200-week moving average 5 times in our data. On average, buying at that moment produced a one-year return of +71.7%. These dips have historically been decent entry points. These episodes lasted 30 weeks on average.
Is APLS a good value right now?
Here's what our data says about APLS as of 2026-05-15: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 78 (overbought). Free cash flow is currently negative. Return on equity is 46.0%. Price-to-book is 12.7x. This is not a buy or sell recommendation — always do your own research.
How does APLS compare to the S&P 500?
Over the past 7.7 years, $100 invested in APLS would have grown to $274, compared to $314 for the S&P 500. That's 14.0% annualized vs 16.1% for the index. APLS has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-05-15